Literature DB >> 7902280

Heterozygous apolipoprotein C-II deficiency: lipoprotein and apoprotein phenotype and RsaI restriction enzyme polymorphism in the Apo C-IIPadova kindred.

C Gabelli1, C Bilato, S Santamarina-Fojo, S Martini, H B Brewer, G Crepaldi, G Baggio.   

Abstract

Deficiency of apolipoprotein C-II (apo C-II), the cofactor for lipoprotein lipase, results in the familial chylomicronaemia syndrome characterized by severe hypertriglyceridaemia and fasting chylomicronaemia. To investigate the biochemical features of the heterozygous state for apo C-II deficiency, we characterized the lipid, lipoprotein and apolipoprotein profiles in 18 relatives of two affected individuals (brother and sister) homozygous for the apo C-IIPadova gene defect which results in the synthesis of a truncated 36 amino acid apolipoprotein. Carrier status was established in first degree relatives as well as in seven non-obligate heterozygotes by restriction enzyme analysis of amplified apo C-II genomic DNA using RsaI. No significant differences in lipid, lipoprotein and apo C-II levels were observed in heterozygotes when compared to unaffected family members. Thus, in this study, the carrier state was not associated with hypertriglyceridaemia or reduced plasma levels of apo C-II. However, analysis of amplified DNA from members of the apo C-IIPadova kindred by digestion with the enzyme RsaI, which identifies the mutant apo C-II, permitted the identification of heterozygous family members which could not be recognized by measuring either fasting triglycerides or plasma apo C-II levels. This study provides further evidence that apo C-II deficiency syndrome is a heterogeneous disease not only at the molecular level but also on the clinical ground with variable phenotypic expression in heterozygous individuals from different kindreds.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902280     DOI: 10.1111/j.1365-2362.1993.tb00960.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

1.  Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism.

Authors:  Gissette Reyes-Soffer; Carol Sztalryd; Richard B Horenstein; Stephen Holleran; Anastasiya Matveyenko; Tiffany Thomas; Renu Nandakumar; Colleen Ngai; Wahida Karmally; Henry N Ginsberg; Rajasekhar Ramakrishnan; Toni I Pollin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

2.  A liver-enriched long non-coding RNA, lncLSTR, regulates systemic lipid metabolism in mice.

Authors:  Ping Li; Xiangbo Ruan; Ling Yang; Kurtis Kiesewetter; Yi Zhao; Haitao Luo; Yong Chen; Marjan Gucek; Jun Zhu; Haiming Cao
Journal:  Cell Metab       Date:  2015-03-03       Impact factor: 27.287

Review 3.  Familial dyslipidaemias: an overview of genetics, pathophysiology and management.

Authors:  Sahar B Hachem; Arshag D Mooradian
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Electrophoretic screening for human apolipoprotein C-II variants: repeated identification of apolipoprotein C-II(K19T).

Authors:  H Wiebusch; J R Nofer; A von Eckardstein; H Funke; U Wahrburg; H Martin; E Köhler; G Assmann
Journal:  J Mol Med (Berl)       Date:  1995-07       Impact factor: 4.599

5.  A novel APOC2 gene mutation identified in a Chinese patient with severe hypertriglyceridemia and recurrent pancreatitis.

Authors:  Jingjing Jiang; Yuhui Wang; Yan Ling; Abudurexiti Kayoumu; George Liu; Xin Gao
Journal:  Lipids Health Dis       Date:  2016-01-16       Impact factor: 3.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.